Taldefgrobep Alfa in Adults With Overweight and Obesity

Last updated: March 19, 2026
Sponsor: Biohaven Therapeutics Ltd.
Overall Status: Active - Not Recruiting

Phase

2

Condition

Diabetes Prevention

Hypertriglyceridemia

Obesity

Treatment

Taldefgrobep Alfa

Placebo

Clinical Study ID

NCT07281495
BHV2000-202
  • Ages 18-65
  • All Genders

Study Summary

This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

  1. a. BMI > 30 kg/m2 and BMI < 42 kg/m2, OR b. BMI ≥ 27 kg/m2 and BMI <30 kg/m2 with atleast one weight-related co-morbidity

  2. History of at least one self-reported unsuccessful dietary effort to lose bodyweight.

  3. Stable body weight and stable physical activity within 3 months prior to screeningper participant self-report.

  4. All participants must adhere to protocol contraception requirements

Exclusion

Key Exclusion Criteria:

  1. History of diabetes, including individuals with a HbA1c of ≥ 6.5% at Screening

  2. Non-ambulatory participants, defined as unable to take at least 10 stepsindependently.

  3. Females currently pregnant or breastfeeding, or who intend to become pregnant or tobreastfeed.

  4. Participation in another investigational clinical trial while participating in thisclinical trial

Study Design

Total Participants: 150
Treatment Group(s): 2
Primary Treatment: Taldefgrobep Alfa
Phase: 2
Study Start date:
November 24, 2025
Estimated Completion Date:
September 30, 2026

Connect with a study center

  • Site-001

    Chula Vista, California 91911
    United States

    Site Not Available

  • Site-014

    Montclair, California 97163
    United States

    Site Not Available

  • Site-011

    Sacramento, California 95821
    United States

    Site Not Available

  • Site-018

    Tustin, California 92780
    United States

    Site Not Available

  • Site-020

    Orlando, Florida 32804
    United States

    Site Not Available

  • Site-008

    Palm Springs, Florida 33461
    United States

    Site Not Available

  • Site-015

    St. Petersburg, Florida 33704
    United States

    Site Not Available

  • Site-007

    Chicago, Illinois 60625
    United States

    Site Not Available

  • Site-016

    Indianapolis, Indiana 46254
    United States

    Site Not Available

  • Site-010

    Baton Rouge, Louisiana 70808
    United States

    Site Not Available

  • Site-009

    Metairie, Louisiana 70006
    United States

    Site Not Available

  • Site-006

    City of Saint Peters, Missouri 63303
    United States

    Site Not Available

  • Site-003

    Springfield, Missouri 65807
    United States

    Site Not Available

  • Site-019

    Monroe, North Carolina 28112
    United States

    Site Not Available

  • Site-002

    Fargo, North Dakota 58104
    United States

    Site Not Available

  • Site-017

    North Charleston, South Carolina 29405
    United States

    Site Not Available

  • Site-005

    Austin, Texas 78745
    United States

    Site Not Available

  • Site-012

    McKinney, Texas 75069
    United States

    Site Not Available

  • Site-013

    San Antonio, Texas 78229
    United States

    Site Not Available

  • Site-004

    Arlington, Virginia 22205
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.